 Home > Biochemistry News > Biotechnology News > DMD innovative therapies reach key clinical trial endpoints, new drug applications are expected to be submitted early next year

DMD innovative therapies reach key clinical trial endpoints, new drug applications are expected to be submitted early next year

 Last Update: 2021-06-04
 Source: Internet
 Author: User

Tags

boron side effects

melatonin drug test

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

Today, Santhera Pharmaceuticals and ReveraGen BioPharma jointly announced that the innovative therapy vamorolone has reached the primary endpoint and multiple key secondary endpoints in a pivotal Phase 2b clinical trial for the treatment of patients with Duchenne muscular dystrophy (DMD).

DMD is one of the most common childhood neuromuscular diseases.

Vamorolone is a potential "first-in-class" steroid drug originally developed by ReveraGen Biopharma.

▲The mechanism of action of Vamorolone (picture source: Santhera's official website)

In this phase 2b clinical trial, a total of 121 DMD patients aged 4-7 years were randomized to receive different doses of vamorolone, placebo or prednisone.

Vamorolone reached the primary endpoint of the trial.

▲Vamorolone significantly improves the speed of patients from supine to standing (picture source: reference [1])

In addition, compared with the placebo group, two different doses of vamorolone also significantly improved the patient's 6-minute walk test (6-MWT) indicators.

▲Vamorolone significantly improved the patient's 6-minute walk test indicators (picture source: reference [1])

In terms of safety, compared with prednisone, vamorolone caused fewer treatment-related adverse events.

▲Compared with prednisone, Vamorolone did not show the effect of delaying the growth of children (picture source: reference [1])

Note: The original text has been deleted

Reference materials:

[1] Presentation on VISION-DMD topline readout with vamorolone.

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

Related Products

L-Ascorbate-2-Monophosphate Feed Grade

CAS No.: 109620-90-8

Feed Grade

Potassium Sorbate from reliable manufacturer

CAS No.: 590-00-1

Food Grade

Doxycycline Hydrochloride

CAS No.: 10592-13-9

Pharmaceutical Grade

Hot Tags

jobs united states(236)

united states jobs(223)

1 year treasury(277)

1 year subscription(296)

single use technology(195)

ups united states(221)

announcements today(81)

united states logo(227)

80 20 company(94)

healthy food name(42)

Hot Articles

The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.